



Final Appraisal Recommendation

Advice No: 2014 – July 2014

Fluticasone furoate/vilanterol (as trifenate) (Relvar[®] Ellipta[®]▼)

92/22 micrograms and 184/22 micrograms inhalation powder

Submission by GlaxoSmithKline

Recommendation of AWMSG

Fluticasone furoate/vilanterol (Relvar[®] Ellipta[®]▼) is recommended as an option for use within NHS Wales for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product (long-acting beta₂-agonist and inhaled corticosteroid) is appropriate:

- patients not adequately controlled with inhaled corticosteroids and 'as needed' inhaled short acting beta₂-agonists.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1216), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue	GlaxoSmithKline
Date of first issue	July 2014
Last reviewed	December 2017

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2014: fluticasone furoate/vilanterol (Relvar[®] Ellipta[®]▼) 92/22 micrograms and 184/22 micrograms inhalation powder. July 2014.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.